These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31229618)

  • 1. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.
    Shrestha R; Altice FL; Sibilio B; Ssenyonjo J; Copenhaver MM
    Contemp Clin Trials; 2019 Jul; 82():77-84. PubMed ID: 31229618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
    Shrestha R; Altice FL; Karki P; Copenhaver MM
    AIDS Behav; 2018 Aug; 22(8):2640-2649. PubMed ID: 29582199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.
    Shrestha R; Karki P; Altice FL; Huedo-Medina TB; Meyer JP; Madden L; Copenhaver M
    Drug Alcohol Depend; 2017 Apr; 173():107-116. PubMed ID: 28214391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
    Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
    BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment.
    Shrestha R; Altice FL; Huedo-Medina TB; Karki P; Copenhaver M
    AIDS Behav; 2017 May; 21(5):1299-1308. PubMed ID: 27990587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users.
    Shrestha R; Karki P; Altice FL; Dubov O; Fraenkel L; Huedo-Medina T; Copenhaver M
    AIDS Behav; 2018 Apr; 22(4):1228-1238. PubMed ID: 28695388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study.
    Qu D; Zhong X; Xiao G; Dai J; Liang H; Huang A
    Int J Infect Dis; 2018 Oct; 75():52-59. PubMed ID: 30125688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence intervention for HIV-infected persons who use drugs: adaptation, open trial, and pilot randomized hybrid type 1 trial protocol.
    Claborn K; Becker S; Operario D; Safren S; Rich JD; Ramsey S
    Addict Sci Clin Pract; 2018 Apr; 13(1):12. PubMed ID: 29606129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "I think everybody should take it if they're doing drugs, doing heroin, or having sex for money": a qualitative study exploring perceptions of pre-exposure prophylaxis among female participants in an opioid intervention court program.
    Przybyla SM; Cerulli C; Bleasdale J; Wilson K; Hordes M; El-Bassel N; Morse DS
    Subst Abuse Treat Prev Policy; 2020 Nov; 15(1):89. PubMed ID: 33228721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment.
    Ni Z; Altice FL; Wickersham JA; Copenhaver MM; DiDomizio EE; Nelson LE; Shrestha R
    Drug Alcohol Depend; 2021 Feb; 219():108477. PubMed ID: 33422864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC.
    Kuo I; Olsen H; Patrick R; Phillips G; Magnus M; Opoku J; Rawls A; Peterson J; Hamilton F; Kharfen M; Greenberg A
    Drug Alcohol Depend; 2016 Jul; 164():8-13. PubMed ID: 27177804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons.
    Springer SA; Nijhawan AE; Knight K; Kuo I; Di Paola A; Schlossberg E; Frank CA; Sanchez M; Pankow J; Proffitt RP; Lehman W; Pulitzer Z; Thompson K; Violette S; Harding KK;
    BMC Infect Dis; 2022 Apr; 22(1):380. PubMed ID: 35428213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment.
    Copenhaver MM; Lee IC; Baldwin P
    AIDS Behav; 2013 Nov; 17(9):2902-13. PubMed ID: 23835735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.